BOLT - Long Setup Looking for a break above 14.03, Target 17.43, Target 2 $24.93. , Stop signal 11.87.
−1.83USD
−69.20 MUSD
7.88 MUSD
24.09 M
About Bolt Biotherapeutics, Inc.
Sector
CEO
Randall C. Schatzman
Headquarters
Redwood City
Website
Employees (FY)
100
Founded
2015
ISIN
US0977021049
FIGI
BBG00N8MY5V9
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where BOLT is featured.
Frequently Asked Questions
The current price of BOLT is 1.11 USD — it has decreased by 3.48% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Bolt Biotherapeutics, Inc. stocks are traded under the ticker BOLT.
Bolt Biotherapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Bolt Biotherapeutics, Inc. has a max estimate of 8.00 USD and a min estimate of 1.25 USD.
BOLT earnings for the last quarter are −0.43 USD whereas the estimation was −0.50 USD which accounts for 14.00% surprise. Estimated earnings for the next quarter are −0.47 USD. See more details about Bolt Biotherapeutics, Inc. earnings.
Bolt Biotherapeutics, Inc. revenue for the last quarter amounts to 2.53 M USD despite the estimated figure of 1.73 M USD. In the next quarter revenue is expected to reach 1.71 M USD.
Yes, you can track Bolt Biotherapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, BOLT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Bolt Biotherapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 100.00 employees. See our rating of the largest employees — is Bolt Biotherapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Bolt Biotherapeutics, Inc. EBITDA is −72.86 M USD, and current EBITDA margin is −943.52%. See more stats in Bolt Biotherapeutics, Inc. financial statements.